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Abstract
Introduction: Controlled mechanical ventilation and endotoxemia are associated with diaphragm muscle atrophy
and dysfunction. Oxidative stress and activation of inflammatory pathways are involved in the pathogenesis of
diaphragmatic dysfunction. Levosimendan, a cardiac inotrope, has been reported to possess anti-oxidative and
anti-inflammatory properties. The aim of the present study was to investigate the effects of levosimendan on
markers for diaphragm nitrosative and oxidative stress, inflammation and proteolysis in a mouse model of
endotoxemia and mechanical ventilation.
Methods: Three groups were studied: (1) unventilated mice (CON, n =8), (2) mechanically ventilated endotoxemic
mice (MV LPS, n =17) and (3) mechanically ventilated endotoxemic mice treated with levosimendan (MV LPS + L,
n =17). Immediately after anesthesia (CON) or after 8 hours of mechanical ventilation, blood and diaphragm muscle
were harvested for biochemical analysis.
Results: Mechanical ventilation and endotoxemia increased expression of inducible nitric oxide synthase (iNOS)
mRNA and cytokine levels of interleukin (IL)-1β, IL-6 and keratinocyte-derived chemokine, and decreased IL-10, in the
diaphragm; however, they had no effect on protein nitrosylation and 4-hydroxy-2-nonenal protein concentrations.
Levosimendan decreased nitrosylated proteins by 10% (P <0.05) and 4-hydroxy-2-nonenal protein concentrations by
13% (P <0.05), but it augmented the rise of iNOS mRNA by 47% (P <0.05). Levosimendan did not affect the inflammatory
response in the diaphragm induced by mechanical ventilation and endotoxemia.
Conclusions: Mechanical ventilation in combination with endotoxemia results in systemic and diaphragmatic
inflammation. Levosimendan partly decreased markers of nitrosative and oxidative stress, but did not affect the
inflammatory response.
Introduction
Respiratory muscle dysfunction frequently develops in
critically ill patients [1-4]. Clinical entities associated
with respiratory muscle dysfunction in these patients
include systemic inflammation [3,5] and controlled
mechanical ventilation (MV) [6]. Recent data obtained
from both animal and human studies have provided
insight into the biochemical pathways underlying muscle
atrophy and dysfunction in these patients [1,7-9].
Nitrosative and oxidative protein modifications are
increased in the diaphragm during both MV and
experimental sepsis [10,11]. Moreover, protein degradation
is increased in the diaphragm in mechanically ventilated
animals and patients [2,12,13]. Inflammatory cytokines are
well-known modulators of muscle protein turnover during
endotoxemia [14,15] and are increased in the diaphragm
after MV [16,17]. For example, tumor necrosis factor
(TNF)-α activates the proteolytic enzymes caspase-8
and caspase-3 in the diaphragm of mice exposed to
lipopolysaccharide (LPS) [5]. Accordingly, strategies
that reduce oxidative stress or inflammation may limit
respiratory muscle dysfunction due to endotoxemia and
MV [11,17].
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Levosimendan is a cardiac inotrope approved for the
treatment of heart failure in many countries worldwide.
We have recently shown that levosimendan also improves
respiratory muscle function in healthy subjects and
patients with chronic obstructive pulmonary disease
(COPD) [18,19]. The mechanisms of levosimendan include
calcium sensitization of the contractile proteins and
vasodilation through activation of ATP-sensitive potassium
channels [20]. Interestingly, previous studies have shown
that levosimendan reduces inflammation as well as
oxidative and nitrosative stress [21-23]. For instance,
in experimental septic rodents, levosimendan decreases
interleukin (IL)-1β levels [24]. In addition, levosimendan
decreases LPS-induced upregulation of IL-6, nitrite
production and inducible nitric oxide synthase (iNOS)
protein expression in macrophages and fibroblasts
[21]. However, the effects of levosimendan on inflam-
mation and oxidative and nitrosative stress in muscle
have not been investigated, despite the importance of
these pathways in intensive care unit (ICU)-acquired
muscle weakness.
Accordingly, the hypothesis of the present study is that
levosimendan dampens both oxidative and nitrosative
stress and the inflammatory response in the diaphragm
induced by endotoxemia.
Methods
Animals
Experiments were performed using male C57BL/6 mice
aged 19 ± 0.5 weeks and body weight 24 ± 0.3 g (Charles
River Laboratories, Sulzfeld, Germany).
To test the hypothesis that levosimendan dampens
both oxidative and nitrosative stress and the inflammatory
response in the diaphragm induced by MV and experi-
mental sepsis, 42 mice were divided into 3 groups: (1)
unventilated controls (CON, n =8), (2) MV and LPS (MV
LPS, n =17) and (3) MV and LPS + levosimendan (MV
LPS + L), n =17). The effects of MV on inflammatory
markers in mice have been investigated previously in our
laboratory [16]. Because patients admitted to the ICU with
endotoxemia often require MV, we used an animal model
in which endotoxemia was administered prior to MV. In
both groups, LPS (10 μg) was administered by intraperito-
neal injection immediately before initiation of MV.
The final choice for the dose of LPS was based on pilot
experiments. In a pilot study, we found that administration
of 100 μg of LPS resulted in high mortality. Nevertheless,
immediately after intraperitoneal injection of a LPS bolus,
one mouse in the MV LPS + L group died and was
excluded from the study. At the start of MV, mice in the
levosimendan group received levosimendan (Orion Pharma,
Espoo, Finland) via the tail vein at a dose of 24 μg/kg body
weight in 5% glucose solution. Subsequently, levosimendan
(0.2 μg/kg/min intravenously) was administered during MV
[20]. The experiments were approved by the regional
animal ethics committee (Nijmegen, the Netherlands)
and performed under the guidelines of the Dutch Council
for Animal Care.
Controlled mechanical ventilation
Mice selected for MV were anesthetized and mechanic-
ally ventilated as described previously [16]. Briefly, mice
were anesthetized with an intraperitoneal injection of a
combination of ketamine, medetomidine, and atropine
(KMA): 7.5 μl/g body weight of induction KMA mix
(consisting of 1.26 ml of ketamine, 100 mg/ml; 0.2 ml of
medetomidine, 1 mg/ml; 1 ml of atropine, 0.5 mg/ml;
and 5 ml of NaCl, 0.9%). Tidal volume was 8 ml/kg
body weight, respiratory rate was 170/min, positive
end-expiratory pressure was 1.5 cmH2O and inspired
oxygen fraction was 0.45. A sterile catheter was
inserted into the carotid artery for continuous blood
pressure measurement and blood sampling at the end
of the experiment (i-STAT blood chemistry analyzer;
Abbott, Hoofddorp, the Netherlands). To maintain
anesthesia, a 5.0 μl/g body weight bolus of KMA mix
(consisting of 0.72 ml of ketamine, 100 mg/ml;
0.08 ml of medetomidine, 1 mg/ml; 0.3 ml of atropine,
0.5 mg/ml; and 18.9 ml of NaCl, 0.9%) was administered
through an intraperitoneal catheter every 30 minutes. The
CON mice were anesthetized and killed without being
mechanically ventilated, as described previously [16].
Tissue collection
Immediately after anesthesia (CON group) or after 8 hours
of MV (MV LPS and MV LPS + L groups), mice were ex-
sanguinated and a combined thoracotomy and laparotomy
was performed. Left and right hemidiaphragm tissues
were rinsed, quickly frozen in liquid nitrogen and stored
at −80°C for later biochemical analysis [16].
Nitrotyrosine
Protein nitrosylation was evaluated by detection of
nitrotyrosine residues by performing SDS-PAGE, as
described previously [25]. In short, diaphragm muscle
was homogenized in ice-cold buffer (pH 7.2, 10 mM
Tris-maleate, 3 mM ethylene glycol tetraacetic acid
(EGTA), 275 mM sucrose, 0.1 mM dithiothreitol (DTT),
2 mg/ml leupeptin, 2 mg/ml aprotinin, 10 mg/L pepstatin
A, 0.57 mM phenylmethylsulfonyl fluoride) using a
Kinematica Polytron homogenizer (Kinematica, Lucerne,
Switzerland), followed by three cycles of freeze-thawing and
30 minutes of centrifugation at 17,000 g at 4°C. Supernatant
protein content was measured by Bradford analysis, and
20 μg of proteins in Laemmli buffer were analyzed
according to standard Western blotting protocols. Blots
were stained using an anti-nitrotyrosine antibody (clone
1A6; Upstate Biotechnology, Lake Placid, NY, USA) and
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goat anti-mouse IRDye 800CW (LI-COR Biosciences,
Lincoln, NE, USA). Analysis was done using an Odyssey
scanner and Odyssey 2.1 software (LI-COR Biosciences).
Inducible nitric oxide synthase expression
mRNA levels of iNOS were determined by quantitative
PCR (Mm01309902_m1 mouse assay; Applied Biosystems,
Foster City, CA, USA) as described previously [26].
4-Hydroxy-2-nonenal protein
4-Hydroxy-2-nonenal (HNE) protein was analyzed as
follows. Tissue samples were homogenized in 100 volumes
of buffer (20 mM Tris, pH 7.4, 20 mM EGTA, 1 mM DTT,
0.5% SDS, 1 μl/20 mg protease inhibitor cocktail (P8340;
Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands)) in
the Kinematica Polytron homogenizer. Samples were
diluted in standard Laemmli sample buffer and boiled for
2 minutes. Ten microliters of each sample were analyzed
according to standard Western blotting protocols. The
following antibodies were used: anti-HNE (fluorophore
rabbit polyclonal antibody, catalog number 393206;
Calbiochem, Darmstadt, Germany), anti-actin (A2066;
Sigma-Aldrich, St Louis, MO, USA) and IRDye 800CW
goat anti-rabbit immunoglobulin G secondary antibody
(926-32211; LI-COR Biosciences). An Odyssey scanner
and Odyssey application software version 2.1 (LI-COR
Biosciences) were used for analysis of HNE protein
signaling.
Cytokines in diaphragm and plasma
Levels of IL-1β, IL-10, TNF-α, IL-6 and keratinocyte-derived
chemokine (KC) in the diaphragm and IL-1β, IL-10, TNF-α,
IL-6 and KC in plasma were analyzed by enzyme-linked
immunosorbent assay as described previously [27]. To
determine cytokine levels in the diaphragm, the muscle
was homogenized in 100 volumes of ice-cold buffer,
pH 7.2 (10 mM Tris-maleate, 3 mM EGTA, 275 mM
sucrose, 0.1 mM DTT, 2 mg/ml leupeptin, 2 mg/ml
aprotinin, 10 mg/L pepstatin A, 0.57 mM phenyl-
methylsulfonyl fluoride), subjected to three cycles of
freezing and thawing and centrifuged at 17,000 g at 4°C
for 30 minutes [16]. Lower detection limits were 40 pg/ml
for IL-10 and IL-1β; 32 pg/ml for TNF-α; and 160 pg/ml
for IL-6 and KC.
Caspase-3 activity
To assess involvement of proteolysis, we measured caspase-
3 activity as described previously [26]. By using spectropho-
tometry, we determined the caspase-3 activity by meas-
uring the generation of the fluorogenic cleavage product
methylcoumarylamide from the fluorogenic substrate
N-acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin.
MuRF1 and MAFbx expression
mRNA levels of muscle RING finger (MuRF1) and
muscle atrophy factor box (MAFbx) were determined by
quantitative PCR [26]. Levels of MuRF1 and MAFbx
mRNA were normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) mRNA. The forward and reverse
oligonucleotides used were, respectively, as follows: MuRF1:
5′-CAACCTGTGCCGCAAGTG-3′ and 5′-CAACCTCG
TGCCTACAAGATG-3′; MAFbx: 5′-GACTGGACTTCTC
GACTGCC-3′ and 5′-TCAGCCTCTGCATGATGTTC-3′;
and GAPDH: 5′-TGATGGGTGTGAACCACGAG-3′ and
5′-GGGCCATCCACAGTCTTCTG-3′.
Statistical analysis
A log-rank test was performed to test differences in
survival between the MV LPS and MV LPS + L groups.
Differences between groups regarding the time course of
mean arterial pressure were evaluated with two-way
analysis of variance (ANOVA). The D’Agostino-Pearson
test was used to verify normal distribution of all parameters
studied. An unpaired Student’s t-test was performed to
evaluate the statistical significance of differences of
the following normally distributed parameters (nitrosylated
proteins and HNE protein between MV LPS and MV
LPS + L animals). Differences in normally distributed
parameters of diaphragm KC, plasma IL-10, IL-6, KC
and caspase-3 activity were analyzed with one-way
ANOVA. The Student-Newman-Keuls post hoc test
was used to test the probability level of differences
between nominal divided groups. Differences between
parameters not normally distributed (iNOS mRNA;
diaphragm IL-1β, IL-10, TNF-α, IL-6, plasma IL-1β and
TNF-α; MuRF1 and MAFbx mRNA) were analyzed with
one-way ANOVA and Kruskal-Wallis and Dunn’s post hoc
tests. For statistical analysis of cytokine measurements,
the value of the detection limit was used for samples
that did not reach the detection limit. GraphPad
Prism software was used to conduct statistical analysis
(GraphPad Software, La Jolla, CA, USA). A probability
level of <0.05 was considered significant. All data are
presented as mean ± SD.
Results
Animal characteristics
Blood pressure decreased progressively in both groups
during 8 hours of MV (Figure 1) (P =0.09), despite
volume therapy (0.3 ml/hr). Blood gas analysis results at
the end of the experiments are shown in Table 1. The
alveolar-arterial (A-a) oxygen gradient was high after
8 hours of MV in both groups (Table 1). During 8 hours
of MV, 30% of the animals in the MV LPS group died
(n =5: respectively, 4 hours, 5 hours and 5½ hours,
and two mice died after 6 hours of MV). In the
levosimendan-treated group, 12% (n =2) died before the
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end of the planned duration of MV (after 5 and 7½
hours of ventilation, respectively; P =0.2 between
groups). Animals that did not survive until the end of
the study were excluded from further biochemical
analysis. Accordingly, 8 CON mice, 12 MV LPS mice
and 14 MV LPS + L mice were included for biochemical
analysis.
Nitrosative and oxidative stress
To investigate the effects of levosimendan on nitrosative
and oxidative stress in endotoxemic, mechanically
ventilated mice, diaphragms were analyzed for iNOS
expression, protein nitrosylation and HNE protein
concentration. Diaphragm iNOS expression was signifi-
cantly increased by 274% in LPS-exposed, ventilated
mice (P <0.05 versus CON) (Figure 2A). Unexpectedly,
levosimendan enhanced the expression of iNOS by 47%
(Figure 2A) (P <0.05 for MV LPS versus MV LPS + L), but
decreased diaphragm protein nitrosylation by 10%
(Figure 2B,C) (P <0.05 for MV LPS versus MV LPS + L).
Diaphragm HNE protein concentration was not significantly
different between MV LPS and CON animals. Levosimendan
decreased the amount of HNE proteins in the diaphragm
by 13% compared with MV LPS (Figure 2D,E) (P <0.05 for
MV LPS versus MV LPS + L).
Inflammation
In MV LPS mice, proinflammatory cytokines were
significantly upregulated in diaphragm muscle and
plasma (Figures 3 and 4). Levosimendan did not affect this
inflammatory response.
Caspase-3 and E3 ubiquitin ligases
Caspase-3 and the E3 ubiquitin ligases MuRF1 and
MAFbx were analyzed as measures of muscle proteolysis.
No differences in caspase-3 activity or MuRF1 mRNA were
observed between groups. MAFbx expression was signifi-
cantly increased in MV LPS and MV LPS + L animals
compared with controls (ratios to GAPDH: 27 ± 12 for
CON, 102 ± 35 for MV LPS and 114 ± 47 for MV LPS + L).
Levosimendan did not affect expression of MAFbx in
ventilated endotoxemic mice.
Discussion
The main findings of the present study are that (1)
levosimendan decreased protein nitrosylation and markers
of oxidative stress in the diaphragm of endotoxemic
mechanically ventilated mice, but that (2) levosimendan did
not attenuate diaphragmatic and systemic inflammatory
responses, diaphragmatic iNOS and E3 ubiquitin ligase
expression or caspase-3 activity.
Figure 1 Mean arterial pressure during 8 hours of mechanical ventilation. LPS, Lipopolysaccharide; MV LPS, Mechanically ventilated
endotoxemic mice; MV LPS + L, Mechanically ventilated endotoxemic mice treated with levosimendan.
Table 1 Arterial blood gas and alveolar-arterial gradient after 8 hours of mechanical ventilation and endotoxemia
exposurea
pH PaO2 (mmHg) PaCO2 (mmHg) HCO3 (mmol/L) BE (mEq/L) A-a gradient (mmHg)
MV LPS + L 7.23 ± 0.0 153 ± 11 26 ± 1.3 11 ± 0.8 −16.6 ± 1.0 135 ± 9.4
MV LPS 7.24 ± 0.0 153 ± 14 25 ± 2.5 12 ± 1.0 −15.7 ± 1.3 136 ± 8.3
aValues are mean ± SEM. A-a, Alveolar-arterial; BE, Base excess; LPS, Lipopolysaccharide; MV LPS, Mechanically ventilated endotoxemic mice; MV LPS + L,
Mechanically ventilated endotoxemic mice treated with levosimendan; PaCO2, Partial arterial carbon dioxide tension; PaO2, Partial arterial oxygen tension.
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Effects of endotoxemia and mechanical ventilation on the
diaphragm
LPS in rodents is a widely used model to study the
effects of endotoxemia on organ function, including
respiratory muscles [28-31]. We found increased expression
of iNOS in the diaphragm of these animals. This is in line
with the only previous study in which researchers
investigated a combination of endotoxemia and MV,
where diaphragm weakness was associated with elevated
levels of iNOS protein [10]. In addition, in the present
study, proinflammatory cytokines were upregulated in
the diaphragm of endotoxemic ventilated animals.
This inflammatory response is consistent with earlier
experimental models of either MV or endotoxemia
[16,31,32]. MV and endotoxemia are known to increases
proteolysis in the diaphragm, as supported by, for example,
elevated caspase-3 activity and expression of the E3
ubiquitin ligases MuRF1 and MAFbx [5,33-35].
Expression of MAFbx was also enhanced in our endotoxe-
mic ventilated mice. MuRF1 expression and caspase-3
activity were not elevated in endotoxemic ventilated
mice. This suggests that the proteolytic response to a
combination of MV and endotoxemia is weaker than that
to MV or endotoxemia separately. Reduced proteolysis
could preserve diaphragmatic function. This is sup-
ported by findings in a previous study in rats [10],
where MV was shown to partly prevent the development
of diaphragmatic dysfunction during endotoxemia.
However, it should be acknowledged that, in the present
study, the effect of MV solely on the diaphragm was not
evaluated, as this was not required to test the hypothesis
of the study.
Figure 2 Markers of nitrosative and oxidative stress. (A) Expression of inducible nitric oxide synthase (iNOS) in the diaphragm. iNOS
expression was increased in mechanically ventilated endotoxemic mice (MV LPS) versus unventilated mice (CON) (*P <0.05). iNOS expression
was increased in mechanically ventilated endotoxemic mice treated with levosimendan (MV LPS + L) versus CON and MV LPS (#P <0.05). GAPDH,
Glyceraldehyde 3-phosphate dehydrogenase; L, Levosimendan; LPS, Lipopolysaccharide. (B) Nitrotyrosine concentration in the diaphragm.
Nitrotyrosine concentration was higher in MV LPS mice than in MV LPS + L mice (*P <0.05). OD, Optical density. (C) Representative nitrotyrosine
blot. (D) 4-hydroxyl-2-nonenal (HNE) protein concentration relative to actin concentration in diaphragm. HNE protein concentration was higher
in MV LPS than in MV LPS + L mice (*P <0.05). (E) Representative HNE protein blot.
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It has been shown previously that endotoxemia is
associated with pulmonary inflammation and elevates the
A-a oxygen gradient [36]. In line with those observations,
we found a high A-a gradient in endotoxemic ventilated
mice (Table 1). The A-a gradient was not assessed in con-
trol mice in the present study. We have previously shown
that the A-a oxygen gradient in healthy mice ventilated
for 8 hours was higher than normal (79 ± 21 mmHg) [16],
but it was significantly lower than reported in the present
study for LPS-exposed ventilated mice. This indicates that
systemic effects of LPS further impaired oxygen uptake in
the endotoxemic ventilated groups of the present study.
Effects of levosimendan
Among its inotropic effects through calcium sensitization,
levosimendan has been shown to affect several intracellu-
lar pathways involved in oxidative stress and inflammation
[21,23]. In the present study, levosimendan infusion
decreased nitrosylated protein levels in ventilated endo-
toxemic mice (Figure 2B). Peroxynitrite formation is
one of the chemical reactions involved in the nitrosylation
of tyrosine residues in proteins (Figure 5) [37,38].
Peroxynitrite is an extremely reactive free radical generated
from the reaction between nitric oxide and superoxide
[39]. Nitric oxide is synthesized from L-arginine under the
influence of the three NOS enzymes: iNOS, endothelial
NOS and neuronal NOS [40].
In the present study, levosimendan did not reduce
iNOS expression (Figure 2A) in the diaphragm of
mechanically ventilated endotoxemic animals. This
may suggest that levosimendan reduced peroxynitrite
formation by lowering superoxide levels. Decreased
superoxide levels are expected to be accompanied by
a reduction of markers for oxidative stress. In line
with that assumption, HNE protein levels (a marker
for oxidative stress) were decreased in the diaphragm of
levosimendan-treated mice (Figure 2D). In accordance
with the possible ability of levosimendan to reduce
oxidative stress, a recent investigation showed that
levosimendan treatment increased protective antioxidant
enzyme levels in renal tissues of rats [41]. Myeloperoxidases
can induce tyrosine nitrosylation independently of
peroxynitrite formation (Figure 5) [42]. Interestingly, pre-
vious experimental studies have shown that levosimendan
Figure 4 Plasma cytokines. Levels of interleukin (IL)-10, tumor necrosis factor (TNF)-α, IL-6 and keratinocyte-derived chemokine (KC) were
increased in mechanically ventilated endotoxemic mice (MV LPS) and mechanically ventilated endotoxemic mice treated with levosimendan
(MV LPS + L) (*P <0.05 versus unventilated mice (CON)). L = Levosimendan; LPS, Lipopolysaccharide.
Figure 3 Cytokine levels in diaphragm homogenates. Mechanically ventilated endotoxemic mice (MV LPS) and mechanically ventilated
endotoxemic mice treated with levosimendan (MV LPS + L) had increased levels of interleukin (IL)-1β, IL-6, keratinocyte-derived chemokine (KC)
and decreased level of IL-10 (*P <0.05 versus unventilated mice (CON)). L, Levosimendan; LPS, Lipopolysaccharide.
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reduces myeloperoxidase activity in the heart and spinal
cord [43,44], but this has not been investigated in the
diaphragm. Although we did not specifically investigate
this pathway, we cannot exclude the possibility that
levosimendan decreased protein nitrosylation by reducing
myeloperoxidase activity.
In the present study, levosimendan did not attenuate
the proinflammatory response to endotoxemia and MV
in either plasma or the diaphragm (Figures 3 and 4). The
lack of effect of levosimendan on plasma inflammation
after levosimendan exposure is in line with previous
studies [45,46]. In apparent contrast, in experimental
sepsis induced by cecal ligation and incision, levosimen-
dan did reduce high plasma levels of IL-1β [24]. However,
in our animal model, plasma levels of IL-1β were not
elevated after LPS exposure. Furthermore, levosimendan
did not dampen MAFbx expression in endotoxemic venti-
lated mice. Interestingly, IL-6 is a well-known regulator of
MAFbx gene expression [47]. The absence of an effect of
levosimendan on plasma and diaphragmatic IL-6 levels
could provide an explanation for the absence of a damp-
ened effect of levosimendan on MAFbx expression. The
activation of caspase-3, another essential player in muscle
protein degradation, was reduced in the spleen of septic
animals treated with levosimendan [24]. Also, in cardiac
muscle cells, levosimendan could protect against hydro-
gen peroxide–induced caspase-3 activation [23]. In the
present study, caspase-3 activity in the diaphragm was
unchanged by levosimendan, but was not enhanced
by endotoxemia and MV.
Study limitations
The present study has limitations that should be acknowl-
edged. First, the duration of MV and endotoxemia in the
present study was relatively shorter than is usually the
case in critically ill patients. It should be noted that MV in
mice is challenging because of limited possibilities of vital
function monitoring and the fact that, owing to very low
intravascular volume (approximately 2 ml), no repetitive
samples can be withdrawn for blood gas analysis.
Nevertheless, in the present study, 8 hours of MV resulted
in modulation of important biochemical pathways in the
diaphragm, in line with the results of our previous study
[16]. Therefore, this time period is appropriate for study
Figure 5 Chemical reactions involved in the formation of nitrotyrosine.
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of the effects of levosimendan on activation of inflamma-
tory and proteolytic pathways. A second limitation of our
study is that we did not assess the effects of levosimendan
on diaphragm muscle function. Previously, we have shown
that levosimendan improves diaphragm muscle function,
both in vitro and in vivo, in healthy subjects, in patients
with COPD and in animal models of congestive heart
failure [18,19,48]. We can only speculate that it also will
improve diaphragm function in the current model, but
this should be confirmed in future studies. Third, as MV
of endotoxemic mice is technically challenging, we were
reluctant to invasively monitor cardiac output or tissue
perfusion, which is of potential interest because levosi-
mendan has been shown to both improve cardiac output
and induce vasodilation [20]. Fourth, in the present study,
LPS was used to induce an inflammatory response, and
LPS administration to animals has been proven to be a
predictable model of systemic inflammation [49]. However,
it should be acknowledged that this is a model of sys-
temic inflammation and does not necessarily reflect the
physiological processes observed in human septic shock.
Conclusions
In an animal model of endotoxemia and MV, levosimendan
decreased markers of oxidative and nitrosative stress.
Therefore, our data may suggest that the beneficial effects
of levosimendan in clinical trials [20,50] may partly result
from effects beyond calcium sensitization. The present
study provides a rationale for investigating such a mechan-
ism in a clinical study. In a current randomized clinical trial
(ClinicalTrials.gov identifier NCT01721434), we are investi-
gating levosimendan in patients difficult to wean from the
ventilator.
Key messages
 Levosimendan dampens nitrosative stress in the
diaphragm of mechanically ventilated endotoxemic
mice.
 Levosimendan did not attenuate diaphragmatic
inflammation following 8 hours of MV in
endotoxemic mice.
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